Reuters logo
BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest
September 11, 2017 / 5:18 AM / 2 months ago

BRIEF-Pharming announces conclusion of FDA end of phase 2 interactions on Ruconest

Sept 11 (Reuters) - PHARMING GROUP NV

* PHARMING ANNOUNCES CONCLUSION OF FDA END OF PHASE 2 INTERACTIONS ON RUCONEST FOR PROPHYLAXIS OF HAE

* TO SUBMIT IN Q4 TO FDA FOR REVIEW BLA EFFICACY SUPPLEMENT (SBLA) TO INCLUDE ROUTINE PROPHYLAXIS AGAINST ANGIOEDEMA ATTACKS IN ADOLESCENT AND ADULT PATIENTS WITH HAE​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below